title: Gene-based antibody strategies for prion diseases.
abstract: Prion diseases or transmissible spongiform encephalopathies (TSE) are a group of neurodegenerative and infectious disorders characterized by the conversion of a normal cellular protein PrP(C) into a pathological abnormally folded form, termed PrP(Sc). There are neither available therapies nor diagnostic tools for an early identification of individuals affected by these diseases. New gene-based antibody strategies are emerging as valuable therapeutic tools. Among these, intrabodies are chimeric molecules composed by recombinant antibody fragments fused to intracellular trafficking sequences, aimed at inhibiting, in vivo, the function of specific therapeutic targets. The advantage of intrabodies is that they can be selected against a precise epitope of target proteins, including protein-protein interaction sites and cytotoxic conformers (i.e., oligomeric and fibrillar assemblies). Herein, we address and discuss in vitro and in vivo applications of intrabodies in prion diseases, focussing on their therapeutic potential.
authors.affiliation: IRCCS San Raffaele Pisana, Via di Val Cannuta 247, 00166 Rome, Italy.
authors.forename: Alessio
authors.initials: A
authors.lastname: Cardinale
authors.forename: Silvia
authors.initials: S
authors.lastname: Biocca
references.citation: J Immunol Methods. 1996 Jun 14;193(1):17-27
references.pmid: 8690927
references.citation: PLoS One. 2011;6(12):e29199
references.pmid: 22216210
references.citation: Biotechnology (N Y). 1995 Oct;13(10):1110-5
references.pmid: 9636285
references.citation: Nat Med. 2003 Jan;9(1):129-34
references.pmid: 12514726
references.citation: Methods. 2004 Oct;34(2):171-8
references.pmid: 15312670
references.citation: Immunotherapy. 2010 Mar;2(2):269-82
references.pmid: 20635933
references.citation: Neurosci Lett. 2009 Jul 31;459(1):16-8
references.pmid: 19394405
references.citation: J Neurochem. 2007 Jun;101(6):1516-26
references.pmid: 17542810
references.citation: Mol Immunol. 2008 Jan;45(1):144-51
references.pmid: 17576014
references.citation: Nat Biotechnol. 2009 Jan;27(1):59-65
references.pmid: 19098898
references.citation: Nature. 1993 Jun 3;363(6428):446-8
references.pmid: 8502296
references.citation: Appl Biochem Biotechnol. 2013 Jan;169(1):159-69
references.pmid: 23160949
references.citation: FASEB J. 2012 Oct;26(10):3969-79
references.pmid: 22730440
references.citation: J Neurosci. 2009 Oct 28;29(43):13589-602
references.pmid: 19864571
references.citation: Mol Ther. 2009 Jul;17(7):1187-96
references.pmid: 19367261
references.citation: Biochem J. 2009 Mar 15;418(3):507-15
references.pmid: 19000036
references.citation: Mol Ther. 2010 Aug;18(8):1471-81
references.pmid: 20551911
references.citation: Handb Exp Pharmacol. 2008;(181):343-73
references.pmid: 18071953
references.citation: Nat Biotechnol. 2005 Sep;23(9):1105-16
references.pmid: 16151404
references.citation: Ther Deliv. 2013 May;4(5):615-28
references.pmid: 23647278
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8293-8
references.pmid: 15928093
references.citation: Lancet. 2007 Jun 23;369(9579):2097-105
references.pmid: 17586305
references.citation: Curr Mol Med. 2008 Feb;8(1):2-11
references.pmid: 18289010
references.citation: Annu Rev Neurosci. 2001;24:519-50
references.pmid: 11283320
references.citation: Nat Biotechnol. 2005 Sep;23(9):1126-36
references.pmid: 16151406
references.citation: Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83
references.pmid: 9811807
references.citation: Biochem Biophys Res Commun. 2005 Dec 30;338(4):1791-7
references.pmid: 16288721
references.citation: Lancet Neurol. 2010 Dec;9(12):1164-1172
references.pmid: 20970382
references.citation: J Immunol. 1998 Feb 1;160(3):1489-96
references.pmid: 9570571
references.citation: Curr Opin Mol Ther. 2010 Apr;12(2):240-7
references.pmid: 20373268
references.citation: Science. 1997 Jan 17;275(5298):402-5
references.pmid: 8994041
references.citation: Science. 2010 Feb 26;327(5969):1091-2
references.pmid: 20185716
references.citation: Med Microbiol Immunol. 2009 Aug;198(3):157-74
references.pmid: 19529959
references.citation: Trends Cell Biol. 1995 Jun;5(6):248-52
references.pmid: 14732130
references.citation: Curr Gene Ther. 2011 Jun;11(3):181-8
references.pmid: 21453285
references.citation: J Cell Biol. 2005 Mar 14;168(6):863-8
references.pmid: 15767460
references.citation: MAbs. 2012 Nov-Dec;4(6):686-93
references.pmid: 22929188
references.citation: EMBO J. 2001 Nov 1;20(21):5863-75
references.pmid: 11689427
references.citation: BioDrugs. 2010 Apr 1;24(2):89-98
references.pmid: 20199124
references.citation: Trends Mol Med. 2008 Sep;14(9):373-80
references.pmid: 18693139
references.citation: J Biol Chem. 2005 Jan 7;280(1):685-94
references.pmid: 15513919
references.citation: J Gen Virol. 2008 Aug;89(Pt 8):2055-2061
references.pmid: 18632978
references.citation: Cell Mol Neurobiol. 2011 Oct;31(7):999-1008
references.pmid: 21516351
references.citation: J Biol Chem. 2007 Mar 23;282(12):8994-9000
references.pmid: 17242404
references.citation: Expert Opin Biol Ther. 2009 Sep;9(9):1189-97
references.pmid: 19653865
references.citation: Annu Rev Biochem. 2006;75:333-66
references.pmid: 16756495
references.citation: EMBO J. 1999 Jun 15;18(12):3193-203
references.pmid: 10369660
references.citation: Mol Ther. 2004 Dec;10(6):1023-31
references.pmid: 15564134
references.citation: EMBO J. 1990 Jan;9(1):101-8
references.pmid: 2153072
references.citation: Mol Ther. 2008 Jun;16(6):1073-80
references.pmid: 18414476
references.citation: Prion. 2012 Sep-Oct;6(4):383-90
references.pmid: 22842862
references.citation: Microbiol Immunol. 2010 Feb;54(2):112-21
references.pmid: 20377745
references.citation: J Virol. 2005 Jul;79(13):8330-8
references.pmid: 15956578
references.citation: PLoS One. 2010 Mar 22;5(3):e9804
references.pmid: 20339552
references.citation: Mol Ther. 2008 Mar;16(3):481-6
references.pmid: 18180775